FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068143857> ?p ?o ?g. }

• W2068143857 endingPage "1361" @default.
• W2068143857 startingPage "1352" @default.
• W2068143857 abstract "To study the pharmacokinetics of a single subcutaneous dose of recombinant human insulin-like growth factor-I (IGF-I) in patients with systemic inflammatory response syndrome in the intensive care unit (ICU). To evaluate the effects of exogenous recombinant human IGF-I on circulating concentrations of IGF-I binding protein-1 (IGFBP-1), IGF-I binding protein-3 (IGFBP-3), and growth hormone in the critically ill patient; to assess the safety of the subcutaneous administration of 40 microg/kg of recombinant human IGF-I in these patients; and to investigate any effect this dose might have on nitrogen balance, creatinine clearance, and serum electrolyte and lipid concentrations.Open-labeled, noncontrolled, prospective, single-dose study of eight fully evaluable ICU patients with systemic inflammatory response syndrome.ICUs in a teaching hospital and a linked district general hospital in England.Nine patients were examined, eight of whom were fully evaluable.Subcutaneous administration of 40 microg/kg of recombinant human IGF-I.Blood samples were taken 24 hrs before the subcutaneous injection of 40 microg/kg of recombinant human IGF-I, and for 48 hrs thereafter. Urine was collected throughout this period. Serum concentrations of IGF-I, IGFBP-1, IGFBP-3, growth hormone, and insulin were measured by radioimmunoassay. IGF-I concentrations (median and range) increased significantly above baseline values (35 ng/mL [20 to 144]) from 15 mins (p < .02) until 10 hrs (p < .02) after injection of recombinant human IGF-I. Peak IGF-I concentrations were sustained from 2 hrs (90.5 ng/mL [23 to 228]) to 5 hrs (88.5 ng/mL [29 to 300]). By 24 hrs, circulating IGF-I concentrations had returned to baseline values. Baseline IGF-I concentrations were extremely low, and although peak values were three times greater, these values only approached the fifth percentile of defined reference ranges for normal values. Compared with values in less seriously ill patients, maximum IGF-I concentrations were reached earlier, the elimination half-life was shorter, clearance was more rapid, and the apparent volume of distribution was similar. IGFBP-3 concentrations also increased after recombinant human IGF-I injection, and at 3 to 4 hrs were significantly elevated, from 30 mins (p = .04) to 8 hrs (p = .04). There was marked between-patient variability in changes in circulating IGF-I, and IGFBP-1, and IGFBP-3 concentrations. More severely ill patients had the lowest circulating IGF-I concentrations and the least response to exogenous recombinant human IGF-I. Elevated baseline circulating growth hormone concentrations (2.3 ng/mL, range 0.8 to 4 [5.1 mU/L, 1.5 to 8]) were significantly depressed from 4 hrs (0.5 ng/mL, 0.5 to 1.5 [1 mU/L, 1 to 3], p = .01) to 6 hrs (0.8 ng/mL, 0.5 to 4 [1.5 mU/L, 1 to 8], p = .02) after recombinant human IGF-I administration.We observed no adverse effects (e.g., hypoglycemia) that could be attributed to recombinant human IGF-I therapy." @default.
• W2068143857 created "2016-06-24" @default.
• W2068143857 creator A5002249012 @default.
• W2068143857 creator A5008074768 @default.
• W2068143857 creator A5027521847 @default.
• W2068143857 creator A5029274763 @default.
• W2068143857 creator A5030816592 @default.
• W2068143857 date "1997-08-01" @default.
• W2068143857 modified "2023-10-17" @default.
• W2068143857 title "Administration of human recombinant insulin-like growth factor-I in critically ill patients" @default.
• W2068143857 cites W1972083618 @default.
• W2068143857 cites W1986824961 @default.
• W2068143857 cites W2000293700 @default.
• W2068143857 cites W2015226336 @default.
• W2068143857 cites W2024067973 @default.
• W2068143857 cites W2026771881 @default.
• W2068143857 cites W2030378687 @default.
• W2068143857 cites W2033503688 @default.
• W2068143857 cites W2038833653 @default.
• W2068143857 cites W2042407186 @default.
• W2068143857 cites W2043169238 @default.
• W2068143857 cites W2054800937 @default.
• W2068143857 cites W2059156857 @default.
• W2068143857 cites W2061425680 @default.
• W2068143857 cites W2063507321 @default.
• W2068143857 cites W2066114232 @default.
• W2068143857 cites W2067859720 @default.
• W2068143857 cites W2069107191 @default.
• W2068143857 cites W2073154101 @default.
• W2068143857 cites W2074020347 @default.
• W2068143857 cites W2074675750 @default.
• W2068143857 cites W2076269126 @default.
• W2068143857 cites W2081096579 @default.
• W2068143857 cites W2091981957 @default.
• W2068143857 cites W2098221348 @default.
• W2068143857 cites W2106605065 @default.
• W2068143857 cites W2111666458 @default.
• W2068143857 cites W2147907511 @default.
• W2068143857 cites W2154712906 @default.
• W2068143857 cites W2419477497 @default.
• W2068143857 cites W4248765561 @default.
• W2068143857 doi "https://doi.org/10.1097/00003246-199708000-00023" @default.
• W2068143857 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9267949" @default.
• W2068143857 hasPublicationYear "1997" @default.
• W2068143857 type Work @default.
• W2068143857 sameAs 2068143857 @default.
• W2068143857 citedByCount "53" @default.
• W2068143857 countsByYear W20681438572012 @default.
• W2068143857 countsByYear W20681438572013 @default.
• W2068143857 countsByYear W20681438572014 @default.
• W2068143857 countsByYear W20681438572015 @default.
• W2068143857 countsByYear W20681438572018 @default.
• W2068143857 countsByYear W20681438572019 @default.
• W2068143857 countsByYear W20681438572022 @default.
• W2068143857 countsByYear W20681438572023 @default.
• W2068143857 crossrefType "journal-article" @default.
• W2068143857 hasAuthorship W2068143857A5002249012 @default.
• W2068143857 hasAuthorship W2068143857A5008074768 @default.
• W2068143857 hasAuthorship W2068143857A5027521847 @default.
• W2068143857 hasAuthorship W2068143857A5029274763 @default.
• W2068143857 hasAuthorship W2068143857A5030816592 @default.
• W2068143857 hasConcept C104317684 @default.
• W2068143857 hasConcept C112705442 @default.
• W2068143857 hasConcept C126322002 @default.
• W2068143857 hasConcept C134018914 @default.
• W2068143857 hasConcept C176685330 @default.
• W2068143857 hasConcept C177713679 @default.
• W2068143857 hasConcept C2776390293 @default.
• W2068143857 hasConcept C2780026642 @default.
• W2068143857 hasConcept C2987404301 @default.
• W2068143857 hasConcept C40767141 @default.
• W2068143857 hasConcept C55493867 @default.
• W2068143857 hasConcept C71924100 @default.
• W2068143857 hasConcept C86803240 @default.
• W2068143857 hasConceptScore W2068143857C104317684 @default.
• W2068143857 hasConceptScore W2068143857C112705442 @default.
• W2068143857 hasConceptScore W2068143857C126322002 @default.
• W2068143857 hasConceptScore W2068143857C134018914 @default.
• W2068143857 hasConceptScore W2068143857C176685330 @default.
• W2068143857 hasConceptScore W2068143857C177713679 @default.
• W2068143857 hasConceptScore W2068143857C2776390293 @default.
• W2068143857 hasConceptScore W2068143857C2780026642 @default.
• W2068143857 hasConceptScore W2068143857C2987404301 @default.
• W2068143857 hasConceptScore W2068143857C40767141 @default.
• W2068143857 hasConceptScore W2068143857C55493867 @default.
• W2068143857 hasConceptScore W2068143857C71924100 @default.
• W2068143857 hasConceptScore W2068143857C86803240 @default.
• W2068143857 hasIssue "8" @default.
• W2068143857 hasLocation W20681438571 @default.
• W2068143857 hasLocation W20681438572 @default.
• W2068143857 hasOpenAccess W2068143857 @default.
• W2068143857 hasPrimaryLocation W20681438571 @default.
• W2068143857 hasRelatedWork W1983848345 @default.
• W2068143857 hasRelatedWork W1985557198 @default.
• W2068143857 hasRelatedWork W2004915280 @default.
• W2068143857 hasRelatedWork W2055103711 @default.
• W2068143857 hasRelatedWork W2073257928 @default.
• W2068143857 hasRelatedWork W2128386570 @default.

• next